Ultra‑Sensitive Analytical Platform for Absolute Quantitation of Nitrosamines (Absolute Quantitation of Nitrosamines, Tech ID: 21‑013)
Technology Overview: This technology enables absolute quantitation of nitrosamines at ultra‑trace levels using advanced analytical techniques. The platform addresses a critical regulatory and safety challenge in pharmaceutical and chemical manufacturing, where nitrosamine impurities must be detected and controlled at parts‑per‑billion or lower. The method improves accuracy, repeatability, and regulatory compliance.
Industry Pain Point: Existing analytical methods struggle with reliable quantitation of trace nitrosamines under evolving regulatory standards.
NJIT Solution: This platform delivers high‑accuracy, absolute quantitation suitable for regulatory‑grade analysis.
Key Features & Advantages
- Ultra‑low detection limits
- Absolute quantitation (not relative estimation)
- High reproducibility and accuracy
- Supports regulatory compliance
Development Stage: TRL 3–4 – Laboratory validation demonstrated.
Target Markets
- Pharmaceutical quality control
- Contract analytical services
- Regulatory compliance testing
Market Opportunity
- Global pharmaceutical analytical testing market (2026): ~$8B
- CAGR: ~7–8%
- Projected market size (2035): ~$15–17B
Commercial & IP Details
Inventors: Hao Chen, Qi Wang